Hims & Hers melaporkan hasil kuartal pertama yang beragam

Hims & Hers Health mencatatkan pendapatan yang di bawah target pada kuartal pertama di tengah tekanan margin.

Perusahaan sedang beralih dari obat-obatan GLP-1 racikan menuju kemitraan bermerek dengan Novo Nordisk dan Eli Lilly. Perubahan ini diperkirakan akan memengaruhi margin dalam jangka pendek sekaligus menurunkan risiko hukum yang terkait dengan peracikan obat.

Artikel Terkait

Sun Pharmaceutical Industries posted robust revenue and profit increases for the March quarter. The company noted pressure on EBITDA margins due to higher investments and reduced milestone income. Outlook for the next fiscal year points to steady but moderated expansion.

Dilaporkan oleh AI

ARS Pharmaceuticals held its first quarter 2026 earnings conference call on May 15, highlighting early momentum in the new year. Company executives emphasized growth drivers including expanded access for its neffy product. The call featured forward-looking statements about the firm's commercial progress.

L’Oréal Group posted a 7.6% like-for-like revenue increase to €12.2 billion in the first quarter of fiscal 2026, exceeding analyst expectations. The results marked an acceleration from the previous quarter. CEO Nicolas Hieronimus credited innovation and e-commerce strength for global market share gains.

Dilaporkan oleh AI

Brandon Sim, president and chief executive of Astrana Health, discussed the company's recent performance during a presentation at the Bank of America Global Healthcare Conference on May 12. He highlighted rapid growth and positive first-quarter outcomes. The value-based care provider continues to expand while maintaining profitability.

 

 

 

Situs web ini menggunakan cookie

Kami menggunakan cookie untuk analisis guna meningkatkan situs kami. Baca kebijakan privasi kami untuk informasi lebih lanjut.
Tolak